DelveInsight’s “Obsessive Compulsive Disorder Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive-Compulsive Disorder Therapeutics Market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the Obsessive Compulsive Disorder Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Obsessive Compulsive Disorder Drugs Market Outlook

Key Takeaways from the Obsessive Compulsive Disorder Market Report

• In March 2025, Biohaven Pharmaceuticals Inc. announced a study’s purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD).
• In March 2025, Yale University announced a study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies will be the change from baseline of placebo vs. active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the end of Week 12.
• Among the 7MM, the United States had the largest Obsessive-Compulsive Disorder Drugs Market Share in 2023, which accounted for approximately 55% of the total 7MM market.
• The Obsessive-Compulsive Disorder Treatment Market Size in the US was ~USD 600 million in 2023.
• In 2023, selective serotonin reuptake inhibitors (SSRIs) made approximately USD 290 million in revenue across the seven major markets, with antipsychotics ranking second, generating around USD 160 million.
• The Obsessive-Compulsive Disorder Treatment Market Size in EU4 and the UK was ~USD 380 million in 2023.
• The leading Obsessive Compulsive Disorder Companies such as Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., and Allergan plc (now part of AbbVie Inc.) and others.
• Promising Obsessive Compulsive Disorder Pipeline Therapies such as Olanzapine, SXC-2023, Valbenazine Oral Capsule, Escitalopram, Seroquel XR, Sertraline and others.

Stay ahead in the competitive landscape of the Obsessive Compulsive Disorder Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Obsessive Compulsive Disorder Treatment Market Size

Obsessive Compulsive Disorder Epidemiology Segmentation in the 7MM

• Total Obsessive-Compulsive Disorder Prevalent Cases
• Total Obsessive-Compulsive Disorder Diagnosed Cases
• Obsessive-Compulsive Disorder Gender specific Cases
• Obsessive-Compulsive Disorder Severity-specific Cases
• Obsessive-Compulsive Disorder Age-specific Cases

Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @ Obsessive Compulsive Disorder Prevalence

Obsessive Compulsive Disorder Emerging Therapies

• Troriluzole: Biohaven Pharmaceuticals

Troriluzole is a new chemical entity (“NCE”) and tripeptide prodrug of the active metabolite, riluzole. Troriluzole is optimized for improved bioavailability, pharmacokinetics, tolerability, and dosing compared to its active metabolite. Based on its Obsessive-Compulsive Disorder Mechanism of Action, preclinical data, and Obsessive-Compulsive Disorder Clinical Trials, troriluzole has the potential for therapeutic benefit in neurological and neuropsychiatric illnesses.

Obsessive Compulsive Disorder Market Outlook

OCD can be treated using pharmacotherapy, specialized psychotherapy, anatomically targeted treatments, or their combination. First-line treatments include cognitive-behavioral therapy and pharmacotherapy with the selective serotonin reuptake inhibitors (SSRIs). In this article we review evidence-based pharmacotherapies for OCD, as well as alternatives that may be considered in refractory patients. Other treatment modalities are reviewed in other articles in this issue. Unfortunately, even with optimal treatment, many patients continue to experience significant symptoms. Remission of moderate or severe OCD is uncommon, and long-term management is often necessary. The development of new, more effective treatment interventions represents an urgent clinical need.

To learn more about Obsessive Compulsive Disorder Treatment guidelines, visit @ Obsessive Compulsive Disorder Market Drivers and Barriers

Obsessive Compulsive Disorder Companies

Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., and Allergan plc (now part of AbbVie Inc.) and others.

Scope of the Obsessive Compulsive Disorder Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Obsessive Compulsive Disorder Companies– Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., and Allergan plc (now part of AbbVie Inc.) and others.
• Obsessive Compulsive Disorder Pipeline Therapies- Olanzapine, SXC-2023, Valbenazine Oral Capsule, Escitalopram, Seroquel XR, Sertraline and others.
• Obsessive Compulsive Disorder Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Obsessive Compulsive Disorder Unmet Needs, KOL’s views, Analyst’s views, Obsessive Compulsive Disorder Market Access and Reimbursement

Explore the dynamics of the Obsessive Compulsive Disorder Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Obsessive Compulsive Disorder Ongoing Clinical Trials Analysis

Table of Contents

1. Key Insights

2. Obsessive Compulsive Disorder Market Report Introduction

3. Obsessive Compulsive Disorder Market Overview at a Glance

4. Obsessive Compulsive Disorder Executive Summary

5. Obsessive Compulsive Disorder Epidemiology and Market Methodology

6. Disease Background and Overview

7. Obsessive Compulsive Disorder Epidemiology and Patient Population

8. Obsessive Compulsive Disorder Patient Journey

9. OCD Marketed Therapies

10. Obsessive Compulsive Disorder Emerging Therapies

11. Obsessive Compulsive Disorder: The 7MM Market Analysis

12. KOL Views

13. SWOT Analysis

14. OCD Unmet needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market